While we previously provided insight into targeting GFPT2 as a therapeutic strategy for KL co-mutant NSCLC [13], there are no clinically approved drugs to inhibit GFPT2 in a well-tolerated manner. The gene discussed is GFPT2; the disease is non-small cell lung carcinoma.